Back to Results
First PageMeta Content
Chemistry / Anorectics / Phenethylamines / Sibutramine / Management of obesity / Obesity / Orlistat / Cardiovascular disease / Adverse effect / Health / Medicine / Organochlorides


Memorandum to the File NDA[removed]Meridia (sibutramine hydrochloride monohydrate)
Add to Reading List

Open Document

File Size: 174,09 KB

Share Result on Facebook

Company

BP / M.D. / M.P.H / Melanie Coffin Patient / /

Continent

Europe / /

Country

Italy / United States / Australia / /

Event

FDA Phase / /

Facility

Pharmacy University of Washington Sanjay Kaul / University Edward Gregg / Vascular Medicine University of Colorado Denver School / Cardiology University of California San Francisco / Endocrinology University of Missouri Kansas City Allison Goldfine / /

IndustryTerm

investigative site / healthcare system / drug safety reporting systems / educational and patient monitoring tools / treatment of obesity / /

MedicalCondition

obesity-related cancers / JE / obstructive sleep apnea / occlusive peripheral arterial disease / heart disease / cerebrovascular disease / non-fatal myocardial infarction / obesity / inadequately controlled hypertension / cardiac arrest / illness / arrhythmia / non-fatal stroke / diabetic nephropathy / hypertension / disease / undiagnosed cardiovascular disease / tachycardia / peripheral artery occlusive disease / dyslipidemia / current smoking / stroke / occult cardiovascular disease / diabetes / cardiovascular disease / asymptomatic and undetected advanced coronary artery disease / Myocardial infarction / diabetes mellitus / heart failure / chronic disease / coronary artery disease / atrial fibrillation / /

MedicalTreatment

resuscitation / /

OperatingSystem

OSE / /

Organization

Harvard Medical School / Endocrinology Products / C.M. Associate Director office of Surveillance and Epidemiology / Chief Medical Officer Hackensack University Medical Center / University of Washington / Medicine & Physiology Wayne State University School / Cardiology UCLA Lamont Weide / M.D. / Ph.D. Chief / Diabetes & Endocrinology University / Colorado Denver School / office of New Drugs / office of Surveillance and Epidemiology / University of Colorado / Western Oregon University / Johns Hopkins University / University of Missouri / Committee An Advisory Committee / Pediatrics Emory University School / Cardiology University of California San Francisco / office of Surveillance and Epidemiology’s Division of Risk Management / Advisory Committee An Advisory Committee / Professor Division / Vascular Medicine University / FDA / European Union / Center for Drug Evaluation and Research / M.P.H Director Office / Advisory Committee / M.P.H. Professor Emeritus Department / Ministry of Health / /

Person

Amy G. Egan / Mathematical Statistician / Jodi Segal / Mark Avigan / William Hiatt / Curtis J. Rosebraugh / John K. Jenkins / Melanie Coffin / Eric Felner / John M. Flack / Peter Gross / Eric C. Colman / Janet Woodcock / Jessica Henderson / Abraham Thomas / Endocrinology / David Waters / Dennis Dixon / Lamont Weide / Katherine Flegal / Edward Gregg / /

Position

Mathematical Statistician / VP / Professor Division / Huber HB / et al / Director OSE SUBJECT / physician / Acting Director / Division of Pharmacovigilance / Senior Research Scientist / Professor / Deputy Director / Director / Executive / Representative / Deputy Director for Safety Division of Metabolism and Endocrinology Products / Associate Professor / Head / /

Product

Meridia / BP / Changes Being Effected (CBE) supplement / minimally effective drug / United States / /

ProvinceOrState

Oregon / Michigan / /

Region

Latin America / Western Oregon / /

Technology

IND protocol / CAD / /

SocialTag